MedPath

Predictive Value of Dynamic Contrast Enhancement MRI on a Cerebral Tumor Response to Gamma Knife Treatment

Completed
Conditions
Cerebral Metastases
Registration Number
NCT00156585
Lead Sponsor
Martin Lepage
Brief Summary

Hypothesis: the pattern of MRI contrast enhancement after gadolinium injection is different in tumors that respond well to gamma knife.

We are going to acquire sequential T1-weighted images of brain lesions before, during and after injection of Gd-DTPA. This will be repeated before and after a treatment with gamma knife. We will then analyse our results to see if there are common enhancement characteristics between lesions that will respond well to the radiosurgery treatment. Response will be clinically assessed by tumor volume as determined by MRI approximately 4 to 6 months after treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
31
Inclusion Criteria
  • Patient with intracerebral lesion benign or malignant wich are not concerned by the exclusion criteria
Exclusion Criteria
  • Pancranial radiotherapy
  • Residual postop lesion
  • Gliomas
  • Patients < 18 years old
  • Anterior allergic reaction to gadolinium
  • Claustrophobia.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MRI parametersBefore treatment with the Gamma Knife

Tumor volume, Ktrans, ve, time at maximum signal enhancement, maximum signal difference, ADC, basal T1 value

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Faculté de médecine, Université de Sherbrooke

🇨🇦

Sherbrooke, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath